Marquette Asset Management LLC raised its stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) by 89.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 47,166 shares of the company’s stock after purchasing an additional 22,301 shares during the period. Marquette […]
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) – Research analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for Atea Pharmaceuticals in a research report issued to clients and investors on Monday, February 5th. Leerink Partnrs analyst R. Ruiz anticipates that the company will earn ($0.66) per share for the quarter. The consensus estimate […]
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) CEO Jean-Pierre Sommadossi sold 56,910 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $3.85, for a total value of $219,103.50. Following the sale, the chief executive officer now owns 116,557 shares of the company’s […]
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) insider Andrea Corcoran sold 15,843 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $3.84, for a total value of $60,837.12. Following the sale, the insider now owns 670,208 shares of the company’s stock, valued […]
Stonepine Capital Management LLC boosted its stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) by 9.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 752,088 shares of the company’s stock after purchasing an additional 67,580 shares during […]